There are 594 resources available
167P - Neoadjuvant (NEO) versus perioperoperative (PERIOP) chemo-immunotherapy (CT-ICI) according to pathological response (PR) in resectable non-small cell lung cancer (NSCLC): An individual patient data (IPD) analysis
Presenter: Antonio Nuccio
Session: Poster Display session
168P - Surgical outcomes for lung carcinoid tumors: A 5-year experience from a Portuguese center
Presenter: Catarina Pereira Moita
Session: Poster Display session
169P - THASSOS-INTL Türkiye subset: Unveiling treatment patterns and clinical outcomes in resectable early-stage NSCLC
Presenter: Ahmet Sezer
Session: Poster Display session
170P - Real-world (RW) characteristics, treatment (Tx) patterns and biomarker use in patients (pts) with early stage non-small cell lung cancer (ES NSCLC) in Greece: Results of the retrospective INFINITY study
Presenter: Sofia Agelaki
Session: Poster Display session
171P - Prognostic impact of lymph node micrometastasis in T1-2a non-small cell lung cancer
Presenter: Hiroyasu Koga
Session: Poster Display session
172P - Qualitative study to identify drivers and barriers of adherence to adjuvant osimertinib for early-stage EGFR positive non-small cell lung cancer (NSCLC)
Presenter: Narjust Florez
Session: Poster Display session
173P - Clinical and pathological insights into EGFR-mutated early-stage non-small cell lung cancer (NSCLC): Associations with survival, PD-L1 expression, and second primary neoplasms
Presenter: Benedetta Del Rio
Session: Poster Display session
174P - Health-related quality of life (HRQoL) assessment in trials testing tyrosine kinase inhibitors (TKI) or immune checkpoint inhibitors (ICIs) in resectable non-small cell lung cancer (NSCLC)
Presenter: Fabio Salomone
Session: Poster Display session
175TiP - ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Presenter: Sabine Schmid
Session: Poster Display session
176TiP - Perioperative adebrelimab plus chemotherapy for resectable non-small cell lung cancer harboring EGFR mutations: A multicenter, phase II trial
Presenter: Gebang Wang
Session: Poster Display session